Assay

Cell-Based Assays World Industry and Market 2018-2028 - Visiongain Report

Retrieved on: 
Wednesday, September 19, 2018
Assay, Biochemistry, Titration, Compound annual growth rate

The revenue of the cell-based assays market in 2017 is estimated at $13bn and is expected to grow at a CAGR of 9.2% in the first half of the forecast period.

Key Points: 
  • The revenue of the cell-based assays market in 2017 is estimated at $13bn and is expected to grow at a CAGR of 9.2% in the first half of the forecast period.
  • Visiongain estimated that the consumables and services segments accounted for 74.26% of the market.
  • In this brand new 241-page report you will receive 85 tables and 103 figures- all unavailable elsewhere.
  • The 241-page report provides clear detailed insight into the cell-based assays market.

Viracor Eurofins offers first commercially available letermovir genotypic sequencing test to help healthcare professionals manage CMV

Retrieved on: 
Thursday, September 13, 2018
Chemistry, Organic chemistry, Ethers, Phosphonic acids, Purines, HIV/AIDS, Foscarnet, Ganciclovir, Cidofovir, Human cytomegalovirus, Assay, Cytomegalovirus colitis

Viracor's CMV drug resistance testing options equip healthcare providers with critical information when patients fail to respond to antivirals during prophylaxis or treatment.

Key Points: 
  • Viracor's CMV drug resistance testing options equip healthcare providers with critical information when patients fail to respond to antivirals during prophylaxis or treatment.
  • The newest assay, CMV Resistance: Letermovir, became available in May 2018 as a standalone test, or as a complete panel with the other CMV drugs as CMV Resistance: Letermovir, Ganciclovir, Foscarnet, Cidofovir.
  • Viracor also offers a CMV resistance test for UL54 and UL97, for ganciclovir, foscarnet and cidofovir.
  • These new assays add to Viracor's menu of CMV testing options that help physicians across the continuum of care for immunocompromised patients with CMV.

Cell Viability Assays Market, 2023

Retrieved on: 
Thursday, September 13, 2018
Chemistry, Biology, Cell biology, Laboratory techniques, Viability assay, Assay, Resazurin, MTT assay, Flow cytometry, Calcein, Viability, Cytotoxicity

The "Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
  • The global cell viability assays market is projected to reach USD 4.16 billion by 2023 from USD 2.78 billion in 2018, at a CAGR of 8.4%.
  • The report analyzes the global cell viability assays market by product, cell type, application, end user, and region.
  • Geographically, the global cell viability assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The global cell viability assays market is projected to grow at a CAGR of 8.4%

Retrieved on: 
Wednesday, September 12, 2018
Biology, Cell biology, Nature, Laboratory techniques, Assay, Biochemistry, Titration, Viability assay, Stem cell

On the basis of cell type, the cell viability assays market is segmented into human cells, animal cells, and microbial cells.The human cells segment is expected to register the highest CAGR during the forecast period.

Key Points: 
  • On the basis of cell type, the cell viability assays market is segmented into human cells, animal cells, and microbial cells.The human cells segment is expected to register the highest CAGR during the forecast period.
  • On the basis of application, the cell viability assays market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications.
  • North America is expected to account for the largest share of the global cell viability assays market in 2018.
  • The report analyzes the various cell viability products and their adoption pattern.It aims at estimating the market size and future growth potential of the global cell viability assays market for different segments such as products, cell types, applications, end users, and regions.

Saliva Collection Aid: How to Collect the Best Saliva Samples

Retrieved on: 
Tuesday, September 11, 2018
Chemistry, Excretion, Saliva, Assay, Nature, Biology

CARLSBAD, Calif., Sept. 11, 2018 /PRNewswire-PRWeb/ -- The emergence of the Saliva Collection Aid in 2012 marked a milestone in the history of saliva collection devices. "

Key Points: 
  • CARLSBAD, Calif., Sept. 11, 2018 /PRNewswire-PRWeb/ -- The emergence of the Saliva Collection Aid in 2012 marked a milestone in the history of saliva collection devices. "
  • In retrospect, many early saliva collection techniques in the published literature were causing interference with assay quality.
  • Many investigators consider saliva collection a novel decision, but research shows that sample collection has a tremendous impact on data quality.
  • Exclusively from Salimetrics, all SalivaBio products are extensively tested to minimize or eliminate variability from saliva collection and have been optimized for collection with participant-specific groups.

Cell Viability Assays Market Worth $4.16 Billion by 2023

Retrieved on: 
Wednesday, September 5, 2018
Biology, Nature, Cell biology, Assay, Biochemistry, Titration, Viability assay, Stem cell, Plate reader

On the basis of product, the consumables segment is expected to account for the largest share of the Cell Viability Assays Market in 2018.

Key Points: 
  • On the basis of product, the consumables segment is expected to account for the largest share of the Cell Viability Assays Market in 2018.
  • Based on application, the Cell Viability Assays Market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications.
  • In 2018, the drug discovery & development application segment is expected to account for the largest share of the global Cell Viability Assays Market.
  • North America is expected to account for the largest share of the Cell Viability Assays Market in 2018, followed by Europe and Asia Pacific.

Multiplex Assay Market to Witness Enhance Demand From Research & Development, Biomarker Discovery and Drug Applications Till 2021 | Million Insights

Retrieved on: 
Tuesday, September 4, 2018
Laboratory techniques, Chemistry, Scientific method, Multiplex, Learning, Assay, High-throughput screening

On a commercial scale, multiplex assay is normally used in high-throughput screening settings in which many specimens are analyzed using a multiplex assay.

Key Points: 
  • On a commercial scale, multiplex assay is normally used in high-throughput screening settings in which many specimens are analyzed using a multiplex assay.
  • A multiple assay may not be a high-throughput compulsorily, but a single multiplex assay produces data for a large number of analytes.
  • Therefore, with the growing popularity of multiplex assays in research worldwide, the market of multiplex assay witnesses a trajectory growth for the assessment period.
  • Multiplex assay market is segmented into multiplex polymerase chain reaction, multiplex arrays, planar assays, bead-based assays, SIMOA technology, gold-nano particle technology, antibody assays and cytometric bead-based assays.

Global Transplant Diagnostics Market Size, Share & Trends Analysis Report 2018-2024

Retrieved on: 
Friday, August 31, 2018
Medicine, Chemistry, Biology, Biotechnology, Organ transplantation, Assay, Personalized medicine

The "Transplant Diagnostics Market Size, Share & Trends Analysis Report By Technology (Molecular Assays, Non-Molecular Assays), By Product (Reagents & Consumables, Instruments), And Segment Forecasts, 2018 - 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transplant Diagnostics Market Size, Share & Trends Analysis Report By Technology (Molecular Assays, Non-Molecular Assays), By Product (Reagents & Consumables, Instruments), And Segment Forecasts, 2018 - 2024" report has been added to ResearchAndMarkets.com's offering.
  • The global transplant diagnostics market size is expected to reach USD 895.2 million by 2024 It is projected to expand at a CAGR of 7.6% over the forecast period.
  • Increasing number of patients suffering from chronic diseases frequently leading to organ failure is creating an upsurge in demand for transplant procedures.
  • In addition, adoption of stem cell therapy and personalized medicine is escalating, thereby influencing demand for transplant diagnostics.

Global In-vitro Toxicology Testing Market Report: Size, Share & Trends Analysis 2014-2025

Retrieved on: 
Friday, August 31, 2018
Animal testing, Laboratory techniques, Alternatives to animal testing, Toxicology, Chemistry, Biology, In vitro, Nature, Assay, Toxicology testing, Model organism

The "In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report By Technology, By Method (Cellular Assay, Biochemical Assay, In Silica, Ex-vivo), By Application, By End-Use, By Region, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report By Technology, By Method (Cellular Assay, Biochemical Assay, In Silica, Ex-vivo), By Application, By End-Use, By Region, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global in-vitro toxicology testing market size is expected to reach USD 26.98 billion by 2025, progressing at a CAGR of 11.4% during the forecast period.
  • Technological advancements in computational biology along with introduction of novel efficient algorithms help in conduct of efficient stimulation of in-silico animal models.
  • This, in turn, has significantly curtailed the need for animal models for clinical studies, thereby providing a fillip to the market.

Abreos Biosciences Announces Partnership with CLIA/CAP Certified Laboratory, ResearchDx

Retrieved on: 
Thursday, August 30, 2018
Immunosuppressants, Natalizumab, Chemistry, Pharmacology, Assay, Therapeutic drug monitoring, Health care

Together with ResearchDx, Abreos has developed moNATor, its first commercial product for therapeutic drug monitoring of Tysabri (Natalizumab).

Key Points: 
  • Together with ResearchDx, Abreos has developed moNATor, its first commercial product for therapeutic drug monitoring of Tysabri (Natalizumab).
  • "We are excited to launch the moNATor assay for the monitoring of therapeutic levels of Tysabri (Natalizumab)" said Shelly Gunn MD, PhD.
  • "The moNATor assay represents a new, highly sensitive class of assays designed to monitor levels of active drugs in the blood.
  • Abreos Biosciences, a San Diego-based biotech company was founded in 2013 by CEO Dr. Bradley Messmer and is focused on developing technologies in precision medicine using their proprietary Veritope platform.